Encavis

Encavis AG is an independent power producer based in Hamburg, Germany, specializing in the acquisition and operation of renewable energy sources, primarily solar and onshore wind farms. Established in 2017 through the merger of Capital Stage AG and CHORUS Clean Energy AG, the company has rapidly positioned itself as a leader in the European renewable energy sector. Encavis focuses on generating stable returns while contributing to the transition towards clean and safe energy supplies. Through its portfolio of solar and wind parks across Europe, the company plays a vital role in promoting sustainable energy solutions.

Mario Schirru

Chief Investment Officer, COO and Board Member

6 past transactions

TokWise

Venture Round in 2023
TokWise is a technology company specializing in green energy portfolio optimization. Its platform offers automated energy data management, advanced portfolio forecasting, real-time position management, and commercial optimization tools to help clients make informed decisions and maximize returns.

Pexapark

Series C in 2023
Pexapark provides an energy investment platform that specializes in software and advisory services for post-subsidy renewable energy sales and risk management. The platform serves as an operating system for the entire energy trading and sales workflow, from price discovery to analytics, execution and monitoring, and covers solar and wind projects in multiple countries. It helps renewable investors structure power sales, complete power purchase agreement transactions, sell energy, and monitor energy risks, with advisory and educational resources to support decision-making. Based in Schlieren, Switzerland.

Pexapark

Series B in 2022
Pexapark provides an energy investment platform that specializes in software and advisory services for post-subsidy renewable energy sales and risk management. The platform serves as an operating system for the entire energy trading and sales workflow, from price discovery to analytics, execution and monitoring, and covers solar and wind projects in multiple countries. It helps renewable investors structure power sales, complete power purchase agreement transactions, sell energy, and monitor energy risks, with advisory and educational resources to support decision-making. Based in Schlieren, Switzerland.

Pexapark

Series B in 2020
Pexapark provides an energy investment platform that specializes in software and advisory services for post-subsidy renewable energy sales and risk management. The platform serves as an operating system for the entire energy trading and sales workflow, from price discovery to analytics, execution and monitoring, and covers solar and wind projects in multiple countries. It helps renewable investors structure power sales, complete power purchase agreement transactions, sell energy, and monitor energy risks, with advisory and educational resources to support decision-making. Based in Schlieren, Switzerland.

Stern Energy

Corporate Round in 2019
Stern Energy is an independent operator focused exclusively on photovoltaics, providing a range of technical, management, and consulting services. The company caters to international players and organizations involved in renewable energy, offering maintenance, specialized services, commercial management, and advisory support. By delivering these services, Stern Energy aims to enhance the efficiency and effectiveness of its clients' operations while ensuring transparency and effective resolution of complex issues.

Hyglos

Series C in 2005
Hyglos GmbH is a German biotechnology company established in 2000, currently operating as a subsidiary of bioMérieux S.A. It specializes in the development of highly specific bacteriophage-derived proteins for improved detection and removal of harmful bacteria and their toxins, such as Lipopolysaccharides (LPS). Hyglos offers a range of products including endotoxin detection kits, endotoxin removal kits, and diagnostic tests for food safety testing, human diagnostics, and antimicrobial applications. Its customer base comprises universities, research institutes, diagnostic companies, biotech companies, food safety testing laboratories, and pharmaceutical companies worldwide. The company's technology enables the production of molecules for effective binding and lysis of bacteria, exploiting the principles of bacteriophage biology. Hyglos' products are sold through distributors globally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.